Literature DB >> 619956

Immunoadherence and complement in cancer-bearing mice.

C Porta, M L Villa, E Clerici.   

Abstract

Shortly after grafting of Ehrlich ascites carcinoma cells, the serum of tumour-bearing mice loses the capacity to mediate immunoadherence phenomena, because of a sharp decrease in the concentration of C3b and C3d, while the cellular receptors for such factors are unaffected by tumour growth. It is suggested that complement is consumed through the alternative pathway which is activated during the inflammatory responses accompanying tumour growth.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 619956      PMCID: PMC2009489          DOI: 10.1038/bjc.1978.3

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  [STUDY OF VARIATIONS IN THE COMPLEMENT LEVEL IN THE COURSE OF CANCER CHEMOTHERAPY].

Authors:  J S BOURDIN; R T SARACINO; I LILLE; F GABAY
Journal:  Acta Unio Int Contra Cancrum       Date:  1964

2.  Serum complement and bacteriophage neutralization titers in human infections, leukemias, and lymphomas.

Authors:  A L BALTCH; W OSBORNE; P A BUNN; L CANARILE; A HASSIRDJIAN
Journal:  J Lab Clin Med       Date:  1960-10

Review 3.  Humoral host defense mechanisms against tumors.

Authors:  C C Ting; R B Herberman
Journal:  Int Rev Exp Pathol       Date:  1976

4.  Serum levels of second component of complement in cancer patients.

Authors:  C M Southam; A H Siegel
Journal:  J Immunol       Date:  1966-09       Impact factor: 5.422

5.  Serum complement level in patients with leukemia.

Authors:  S Yoshikawa; K Yamada; T O Yoshida
Journal:  Int J Cancer       Date:  1969-11-15       Impact factor: 7.396

6.  In vitro synthesis of factor B of the alternative pathway of complement activation by mouse peritoneal macrophages.

Authors:  C Bentley; D Bitter-Suermann; U Hadding; V Brade
Journal:  Eur J Immunol       Date:  1976-06       Impact factor: 5.532

7.  Abnormalities of complement and its components in patients with acute leukemia, Hodgkin's disease, and sarcoma.

Authors:  J L Lichtenfeld; P H Wiernik; M R Mardiney; R M Zarco
Journal:  Cancer Res       Date:  1976-10       Impact factor: 12.701

8.  Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells.

Authors:  K Irie; R F Irie; D L Morton
Journal:  Science       Date:  1974-11-01       Impact factor: 47.728

9.  Increase of serum complement levels in cancer patients with progressing tumors.

Authors:  H Verhaegen; W De Cock; J De Cree; F Verbruggen
Journal:  Cancer       Date:  1976-10       Impact factor: 6.860

10.  Persistence of immunoglobulin and complement components C4 and C3 bound to guinea pig tumor cells.

Authors:  M Segerling; S H Ohanian; T Borsos
Journal:  J Natl Cancer Inst       Date:  1976-07       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.